Background: PB2 cap is critical for the initiation of influenza virus transcription. Results: FluB PB2 cap binds to GDP and m 7 GDP utilizing unique structural features, which is corroborated by data from ITC. Conclusion: FluB PB2 cap has a unique cap recognition mechanism compared with FluA PB2 cap . Significance: We characterize the cap recognition mechanism of FluB PB2 cap , consequently providing insight into inhibitor design targeting FluB PB2 cap .
The influenza virus is subdivided into three different categories: influenza A virus (FluA), 2 influenza B virus (FluB), and influenza C virus (FluC). FluA is well studied as it frequently causes both pandemic and seasonal influenza. FluB mainly infects humans as a cause of seasonal influenza and is also detected in seals (1, 2) . As an important pathogen of influenzaassociated hospitalizations, FluB infection causes influenza and even mortality in humans, predominantly in children (3) (4) (5) . The report for influenza-associated pediatric mortality showed that FluB, as 26% of circulating influenza viruses, caused 38% of all influenza-associated pediatric deaths in the United States during 2010 -2011 (6) . The latest report from the World Health Organization FluNet showed that FluB is prevalent as 24.8% of the seasonal epidemics each year and co-circulates with certain subtypes of FluA, such as FluA (H3N2) (29.5%) and FluA (H1N1) pdm09 (16.5%) viruses. In contrast, FluC has a distant evolutionary relationship with FluA and FluB and causes rare but still severe flu and sometimes local epidemics (7) .
FluB is a negative-sense RNA virus, and its eight viral genome RNA segments (vRNA) encode 11 proteins. PA, PB1, and PB2 subunits form the influenza RNA-dependent RNA polymerase for both transcription and replication of vRNA. In the host nucleus, the polymerase transcribes vRNA by the "cap-snatching" mechanism (8) . In transcription, the cap-binding domain of PB2 (PB2 cap ) binds to the 5Ј cap structures of host pre-mRNAs (9) , and then the cap, together with 10 -13 nucleotides downstream of the cap, is cleaved off by the N-terminal endonuclease domain of PA (10, 11) . Subsequently, the generated 5Ј-capped RNA fragment serves as the primer to synthesize viral mRNA by the PB1 subunit. As a milestone contribution, the newest work from Cusack and co-workers (12, 13) clarified the atomic level assembly mode of the whole polymerase, including PA, PB1, and PB2 subunits and the viral RNA promoter.
The N7-methyl group of guanine in the cap structure of eukaryotic mRNA is essential for FluA to prime transcription (14) . However, FluB polymerase recognizes not only the N7-methyl group of guanine (m 7 G-capped RNAs) but also the unmethylated GpppG-RNAs efficiently (15) . Moreover, FluB polymerase is demonstrated to have a weaker cap binding activity than FluA polymerase (15) . A study recently proved that VX-787, which is an inhibitor targeting FluA PB2 cap , is active against FluA but not against FluB (16) . Taken together, these data suggest that FluB functions differently from FluA during the cap binding process.
The structures of the cap recognition mechanism for FluA PB2 cap have been extensively studied. The structure of FluA PB2 cap (amino acids 318 -483) was first determined by Stephen Cusack and co-workers (9) , and the cap-binding pocket complex with the cap analog m 7 GTP was characterized. Furthermore, the conservative characteristics of the cap-binding pocket were evaluated (17) , and the unliganded structure was solved (17, 18) . Recently, inhibitors targeting the PB2 cap-binding pocket were reported (19, 20) . These efforts provided clear atomic information for FluA PB2 cap and indicated that the conserved cap-binding pocket is indeed a potential drug target. However, because several key amino acids in the cap-binding pocket are different from those of FluA, how FluB PB2 cap functions in the cap binding mechanism and whether the cap-binding pocket of FluB is also a suitable drug target still remain to be resolved. Most recently, the structure of the whole FluB polymerase without cap binding for PB2 subunit was reported (12) . The substrate binding information is still necessary for understanding the cap recognition mechanism of FluB PB2 cap .
In this study, we first report the crystal structure of FluB Q325F PB2 cap with bound m 7 GDP. Compared with FluA PB2 cap , the structure reveals that the guanine and ribose moieties of m 7 GDP invert, resulting in the N7-methyl group and hydroxyl group of guanine facing outward of the binding pocket. We then solved the crystal structures of wild-type FluB PB2 cap and FluB Q325F PB2 cap with bound GDP. Here GDP shows the same cap binding pattern as m 7 GDP, and the side chain of Gln 325 in FluB PB2 cap -GDP shows conformational flexibility. Moreover, we characterize the cap binding affinity and specificity of these FluB PB2 caps and compare them with the FluA PB2 cap by isothermal titration calorimetry (ITC). Our results indicate that the FluB polymerase possesses a novel cap recognition mechanism.
MATERIALS AND METHODS
Cloning, Protein Expression, and Purification-The cDNA encoding amino acids 320 -484 of FluB polymerase PB2 subunit was obtained from influenza B/Jiangxi/BV/2006. 3 The Q325F, W359H, and Y434H mutations (amino acids 320 -484) were constructed using a QuikChange TM site-directed mutagenesis kit (Stratagene) and confirmed by DNA sequencing. FluB PB2 cap (amino acids 318 -484) that contains two more wild-type residues Gly 318 -Leu 319 at the N terminus was cloned and is designated as FluB PB2 cap in the following text. The FluA PB2 cap (amino acids 318 -483) gene from influenza A/Puerto Rico/8/34 (H1N1) was cloned as described previously (17, 22) . All the cDNAs were digested with NdeI and XhoI and inserted into the pET28a vector with a His 6 tag at the N terminus. The recombinant FluB PB2 cap plasmids were overexpressed in Escherichia coli strain BL21(DE3), and FluA PB2 cap was expressed in E. coli strain Rosetta(DE3). Cells were grown at 37°C until an A 600 of 0.8 -1.0 was reached, and then the protein expressions were induced with 0.3 mM isopropyl D-1thiogalactopyranoside (Sigma) at 18°C overnight. Cells were then harvested in a binding buffer (50 mM Tris, pH 8.0, 500 mM NaCl) and lysed by sonication. The cell lysate was centrifuged twice at 38,900 ϫ g at 4°C for 30 min each. The supernatant was filtered with a 0.22-m membrane and purified by metal affinity chromatography using a HiTrap chelating HP column (GE Healthcare). The FluB PB2 cap and FluB Q325F PB2 cap proteins were subjected to thrombin digestion at 4°C overnight, whereas FluA PB2 cap was digested at 22°C for 1 h, and then proteins were applied to a nickel affinity column to remove the His tag and undigested protein followed by purification using Superdex 75 gel filtration chromatography (GE Healthcare). The FluB Q325F PB2 cap was further purified by ion exchange chromatography using a Q column (GE Healthcare). The protein was then dialyzed against buffer containing 10 mM Tris, pH 8.0, 200 mM NaCl for crystal screening or buffer containing 10 mM HEPES, pH 7.4, 150 mM NaCl for isothermal titration calorimetry.
Crystallization-10 mg ml Ϫ1 FluB Q325F PB2 cap proteins were incubated with 5 mM m 7 GTP (Sigma) and 5 mM GDP (Sigma) separately on ice for 1 h. The crystals used for data collection were obtained via the sitting drop vapor diffusion method at 20°C. The FluB Q325F PB2 cap with m 7 GTP grew crystal clusters from 0.2 M ammonium acetate, 0.1 M Tris, pH 8.5, 25% (w/v) PEG 3350 after approximately 2 weeks, and a single crystal was extracted for data collection. The crystal of FluB Q325F PB2 cap with GDP grew from 0.15 M DL-malic acid, pH 7.0, 20% (w/v) PEG 3350 within 2-4 days. 10 -12 mg ml Ϫ1 FluB PB2 cap (amino acids 318 -484) was incubated with 5 mM m 7 GTP, 5 mM, and 10 mM m 7 GDP (Sigma), and 5 mM GDP separately for crystal screening purposes, and only the crystal of FluB PB2 cap with GDP was obtained from 0.2 M sodium formate, 20% (w/v) PEG 3350 within 2 days.
Data Collection and Structure Determination-All of the x-ray diffraction data were collected at Shanghai Synchrotron Radiation Facility (China) beamline BL17U. The corresponding reservoir solutions with a gradient of 5 and 10% (v/v) glycerol as a cryoprotectant for crystals of FluB Q325F PB2 cap -m 7 GDP and FluB Q325F PB2 cap -GDP and with 5% (v/v) glycerol for FluB PB2 cap -GDP were used. After soaking, the crystals were flash cooled in liquid nitrogen and maintained at 100 K in cooled nitrogen gas for data collection. All of the data were processed with HKL 2000. The FluB Q325F PB2 cap -m 7 GDP crystal structure was solved by molecular replacement using Molrep in the CCP4 suite (23) with the H3N2 PB2 cap -m 7 GTP structure (Protein Data Bank code 4EQK) used as a search model. The 424loop was rebuilt manually in Coot (24) . The FluB Q325F PB2 cap -GDP and FluB PB2 cap -GDP were solved with the FluB Q325F PB2 cap -m 7 GDP structure used as a search model. All the initial structures were refined by REFMAC5 (25) and built in Coot (24) . The structure model of FluB Q325F PB2 cap -GDP was further refined with the geometry restraints by the refinement program in PHENIX (26) . The final models were assessed with the program PROCHECK (27) . The final statistics for data collection and structure refinement are presented in Table 1 .
Isothermal Titration Calorimetry-ITC was carried out at 20°C with a MicroCal iTC 200 (MicroCal Inc.). All proteins were desalted into a buffer containing 10 mM HEPES, pH 7.4, 150 mM NaCl with either m 7 GDP or GDP dissolved in the same buffer. For FluA PB2 cap and FluB PB2 cap , 240 -280 M protein (in the cell) and 2.5 mM m 7 GDP or GDP (in the syringe) were used for titration. For FluB Q325F PB2 cap , 85 M protein (in the cell) and 1.2 mM m 7 GDP or GDP (in the syringe) were used. The first injection of 0.5 l was followed by 34 injections of 1 l with a 110-s spacer. All of the data were fitted to a single binding site model using Origin 7.0 program analysis.
RESULTS
The Crystal Structures of FluB Q325F PB2 cap with Bound m 7 GDP and GDP-Unlike FluA PB2 cap , FluB PB2 cap readily precipitated out of solution at room temperature. During protein purification efforts, we noticed that the addition of m 7 GTP improved the stability of FluB PB2 cap , which is similar to FluA PB2 cap . We obtained crystals of m 7 GTP with FluA PB2 cap (17) but not m 7 GTP with FluB PB2 cap . Comparison of the residues of the cap-binding pocket between FluA and FluB revealed that the key difference(s) in the m 7 GTP-binding site (cap-binding pocket) of PB2 cap might result in the weak stability of FluB PB2 cap . Based on the sequence alignment ( Fig. 1 ), Gln 325 , Trp 359 , and Tyr 434 are the three key residues in the cap-binding pocket of FluB PB2 cap that are different from FluA, and we thus mutated these residues to the corresponding residues of FluA PB2 (Q325F, W359H, and Y434H) and screened the three single mutations. FluB W359H PB2 cap was insoluble, and FluB Y434H PB2 cap exhibited the same instability as the wild type.
However, FluB Q325F PB2 cap showed greater stability than the wild type and was used for further crystallographic studies.
We first solved the crystal structure of FluB Q325F PB2 capm 7 GTP at 2.21-Å resolution, and it was refined with an R-factor of 0.176 (R free ϭ 0.242) ( Fig. 2A and Table 1 ). In the crystal structure, there was clear electron density for the substrate without the ␥-phosphate observed (Fig. 3B ), and we therefore named this structure as FluB Q325F PB2 cap -m 7 GDP.
The structure of FluB Q325F PB2 cap -m 7 GDP shares a similar conformation with FluA PB2 cap -m 7 GTP (Protein Data Bank code 4EQK) with a 1.31-Å root mean square deviation mainly in the 424-loop and C-terminal loop (Fig. 2B) . Surprisingly, FluB shows a distinct binding pattern to the substrate in the capbinding pocket (Fig. 2, C and D) . Compared with FluA PB2 capm 7 GTP, the guanine moiety of m 7 GDP in FluB Q325F PB2 cap flips 180°around the long axis of the base, resulting in the N7-methyl group and hydroxyl group facing outward of the binding pocket and leaving room for a water molecule (W3) inside of the pocket. The broadened F o Ϫ F c map (Fig. 3A , green map) suggests oscillation of the N7-methyl group, which may result because it points out into the solvent. In this case, Lys 378 and Gln 408 lose their interaction to the guanine moiety, whereas Arg 334 forms a new 2.59-Å hydrogen bond with the hydroxyl group. Glu 363 keeps conserved hydrogen bonds with the N1 and N2 of the guanine moiety. Trp 359 sandwiches the methylated guanine moiety instead of His 357 in FluA PB2 cap . Phe 406 and Phe 325 (the Q325F mutation) form the same upper cover as FluA PB2 cap for stacking interactions to the guanine moiety (Fig. 3, A and C) . Phe 325 has a 4.52-Å distance to the N7 of the guanine moiety (Fig. 3A) compared with the 3.4-Å distance between Phe 404 and the N7-methyl group in FluA PB2 cap (Fig. 3C) . The ribose moiety is also inverted in the structure, and the ribose hydroxyl groups face inward toward the pocket and are close to Phe 327 and Met 433 . The O4 of the ribose moiety forms a 2.85-Å hydrogen bond with Trp 359 . Although the guanine and ribose moieties invert, the diphosphate moiety of m 7 GDP shows a similar trend as that of m 7 GTP in FluA PB2 cap . (9, 17) , there are also two water molecules (W1 and W2) that are buried among residues Glu 363 , Lys 378 , and Gln 408 . The FluB polymerase recognizes both the m 7 G-capped RNAs and the unmethylated GpppG-RNAs efficiently (15) . The structure of FluB Q325F PB2 cap -m 7 GDP shows the N7-methyl group pointing out toward the solvent. To test whether the unmethylated GpppG-RNA binds in the same orientation, we determined the crystal structure of GDP-bound FluB Q325F PB2 cap . The crystal structure of FluB Q325F PB2 cap -GDP was obtained within 2-4 days after co-crystallization with 5 mM GDP. The 2.29-Å FluB Q325F PB2 cap -GDP structure was refined with an R-factor of 0.185 (R free ϭ 0.250) ( Table 1 ). In the cap-binding pocket here, GDP shows the same conformation as m 7 GDP in FluB Q325F PB2 cap -m 7 GDP (Fig. 3, D and E) .
Gln 325 Is Flexible in the Cap-binding Pocket of Wild-type FluB PB2 cap -The structure of the wild-type FluB PB2 cap with its substrate is essential for understanding how the wild-type residue Gln 325 interacts with substrate. As mentioned above, we failed to crystallize FluB PB2 cap with m 7 GTP even though the addition of m 7 GTP improved the stability of FluB PB2 cap . Based on the successful crystallization of FluB Q325F PB2 cap with m 7 GDP and GDP, we further screened the crystals of wild-type FluB PB2 cap with m 7 GDP and GDP. We obtained crystals and solved the structure of FluB PB2 cap (amino acids 318 -484) bound with GDP but not with the methylated substrate m 7 GDP.
The structure of FluB PB2 cap -GDP was solved to 1.8-Å resolution and refined with an R-factor of 0.170 (R free ϭ 0.230) (Fig.  4, A and B, and Table 1 ). The GDP in the structure (Fig. 4, C and  D) shows the same orientation as the GDP and m 7 GDP in FluB Q325F PB2 cap (Fig. 3, D and A) . There are two molecules in the crystallographic asymmetric unit. In molecule B, the side chain of Gln 325 shows a 3.96-Å distance to GDP (Fig. 4D) , and in molecule A, the side chain of Gln 325 is disordered with weak electron density (Fig. 4C) . These observations suggest that Gln 325 is flexible and may contribute weakly to cap binding of FluB PB2 cap .
Structural analysis revealed that the N7-methyl group is oscillating in FluB Q325F PB2 cap -m 7 GDP (Fig. 3A) and that Gln 325 in the wild-type FluB PB2 cap is more flexible than Phe 325 of the mutant (Fig. 4C) . These data may explain why we could not obtain the crystal of FluB PB2 cap -m 7 GDP. Based on the crystal structures solved in this investigation, we propose a model for wild-type FluB PB2 cap binding to m 7 GDP (Fig. 4E ). In the model, m 7 GDP keeps the same orientation as m 7 GDP in the crystal structure of FluB Q325F PB2 cap -m 7 GDP (Fig. 3A) and is consistent with GDP in FluB Q325F PB2 cap -GDP ( Fig. 3D) and FluB PB2 cap -GDP (Fig. 4, C and D) . The orientation of Gln 325 is the same as that of Gln 325 in FluB PB2 cap -GDP ( Fig. 4D) and is similar to that of Phe 325 in FluB Q325F PB2 cap -m 7 GDP (Fig. 3A) and FluB Q325F PB2 cap -GDP (Fig. 3D ). All three available crystal structures and the model presented here show that the guanine and ribose moieties of substrates invert in FluB PB2 caps compared with those of FluA PB2 cap .
FluB and FluA PB2 caps Show Different Substrate Specificity and Affinity-To investigate the cap binding affinity resulting from the structural differences between FluB and FluA PB2 caps , we examined the affinity of m 7 GDP and GDP to FluA, FluB, and FluB Q325F PB2 caps using ITC, respectively (Fig. 5 ). ITC was carried out at 20°C in a buffer containing 10 mM HEPES, pH 7.4, 150 mM NaCl. Consistent with previous reports (9), FluA PB2 cap was favored a methylated substrate with a dissociation equilibrium constant (K d ) of 17 M for m 7 GDP and 118 M for GDP. In contrast, FluB PB2 cap showed an approximated binding to m 7 GDP (167 M) and GDP (169 M) with about one-tenth of the affinity of FluA PB2 cap to m 7 GDP and slightly weaker affinity to GDP than FluA PB2 cap . Notably, the Q325F mutation significantly improves the affinity of FluB PB2 cap to both m 7 GDP (26.8 M; 6.2-fold) and GDP (4.9 M; 34.5-fold) and shows great specificity for GDP versus m 7 GDP. Compared with FluA PB2 cap , FluB Q325F PB2 cap shows a similar affinity to m 7 GDP and tighter binding characteristics to GDP. These results indicate that FluB PB2 cap possesses different substrate specificity and affinity compared with those of FluA PB2 cap .
DISCUSSION
Influenza B virus has a devastating mortality rate in humans, especially in children (3, 4, 6) , which is an essential characteristic of seasonal influenza. Structural information for FluB PB2 cap , a core executor for the transcription initiation of influenza polymerase, had previously been unknown. The structure of the whole FluB polymerase was reported recently; however, it still lacks substrate binding information for cap snatching (12) . Whether FluB PB2 cap functions with the same cap binding mechanism as FluA is unclear. Conversely, the neuraminidase structures of FluA and FluB viruses show a common drug-binding pocket (28) ; therefore, FluB can be treated with the same clinical drugs, such as oseltamivir (Tamiflu) and zanamivir (Relenza), as FluA. As a potential drug target, whether FluB PB2 cap and FluA PB2 cap can bind to the same inhibitors is currently unknown. Herein, we have determined the structures of substrate-binding FluB PB2 cap and FluB Q325F PB2 cap and characterized their substrate specificity and affinity.
Our results suggest that, unlike FluA PB2 cap , FluB PB2 cap has a novel cap recognition feature. In both structures of FluB wildtype and Q325F PB2 caps , the guanine and ribose moieties of m 7 GDP (GDP) invert around the long axis of the base compared with FluA PB2 cap , leaving the N7-methyl group and hydroxyl group of the guanine moiety facing outward and the ribose hydroxyl group facing toward the cap-binding pocket (Fig. 2) . According to the structure and sequence alignments between FluA and FluB Q325F PB2 caps (Figs. 1 and 2D) , this inversion may be caused by the orientation of Trp 359 in FluB PB2 caps , whereas a His 357 occupies the same position of FluA PB2 cap .
Lys 378 and Gln 408 of FluB PB2 cap lose their interactions with m 7 GDP (GDP) due to the inversion of the guanine moiety, consistent with the report that these two residues contribute less to cap binding (15) . Conversely, Arg 334 of FluB PB2 cap is a newly identified residue utilized for the recognition of the outward facing hydroxyl group of guanine moiety that functions similarly to Lys 376 in FluA PB2 cap (at the corresponding position of Lys 378 of FluB PB2 cap ; Figs. 1 and 2D) . Conservatively, Glu 363 of FluB PB2 cap retains recognition of N1 and N2 of guanine moiety as in FluA (Figs. 1 and 2D) . In conclusion, the available structural information for PB2 caps indicates that both FluA and FluB need an acidic glutamate and an alternative basic residue for the recognition of the guanine moiety in the cap-snatching mechanism (Fig. 2D ). The combination of Trp 359 , Phe 406 , and Gln 325 is used to clamp the guanine moiety and is associated with the weak cap binding of FluB PB2 cap to m 7 GDP. In contrast, the mutation Q325F can recover the affinity of FluB PB2 cap to m 7 GDP (Fig.  5 ). The weak cap binding affinity of methylated substrate to FluB PB2 cap could further explain why the RNA elongation and cap binding activities of the FluB polymerase are lower than those of the FluA polymerase (15) . However, it is unclear whether some other factors contribute to the unexpectedly low affinity of the FluB PB2 cap to substrates under physiological conditions.
The inversion of the guanine moiety also allows FluB PB2 cap to accept GDP well. The ITC results revealed that FluB PB2 cap has an equal affinity for GDP and m 7 GDP (Fig. 5) . The side chain of Gln 325 shows conformational flexibility in molecule A of FluB PB2 cap -GDP (Fig. 4C) . These observations suggest that the flexibility of Gln 325 may contribute to the weak recognition of the N7-methyl and unmethylated substrates.
In contrast, both FluB Q325F PB2 cap and FluA PB2 cap could distinguish m 7 GDP from GDP (Fig. 5 ) because Phe 325 in FluB Q325F PB2 cap and Phe 404 in FluA PB2 cap are used for rigid packing to the N7-methyl group (Fig. 3, A and C) . In a comparison of FluA PB2 with FluB PB2, FluB PB2 could recognize GpppG for cap primer generation, although it fails in elongation (15) . It has been reported that the transcript from the nonmethylated cap primer could not be translated by host ribosomes (29 -31) . Whether the recognition of non-methylated cap primer by FluB has a physiological role is unclear; therefore further investigation is needed.
Cap-binding proteins in humans, such as the heterodimeric nuclear cap-binding complex (32) and eIF4E (33) , show a higher affinity to methylated substrates and significant discrimination against non-methylation (34 -36) . Therefore, the cap recognition of FluB PB2 cap for both m 7 GDP and GDP with a low affinity provides a good opportunity for rational inhibitor design. First, the binding cavity allows FluB PB2 cap to accommodate both GDP and m 7 GDP derivatives. Second, a modification of N3 of the guanine moiety, such as the addition of a hydroxyl to N3 (Protein Data Bank code 3G9L), may recover its interaction with Lys 378 and Gln 408 . FluA PB2 cap may also utilize this modification, which has the potential to interact with Arg 332 of FluA PB2 cap (Fig. 2D ). Third, N7 of the guanine moiety could be modified to interact with Gln 325 . Finally, modification of the ribose hydroxyl groups facing inward toward the pocket is likely to build a stronger interaction to Tyr 434 or Phe 327 . In summary, our data have provided the structural and biochemical basis for cap recognition of FluB PB2 cap , which in turn helps in understanding how FluB PB2 cap executes the cap binding process and provides further insight into rational inhibitor design targeting FluB PB2 cap .
